BLUDOTCinactive

IMMUCOR INC

Healthcare·Nephrology·Commercial
Nephrology

IMMUCOR INC (BLUD): 4 pipeline candidates · ~19 mo cash runway. Updated within the last hour.

6.9/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway5.2

18.7 months

Financial Health5.0

D/E 4.46 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for IMMUCOR INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$10.0M

Quarterly Burn

$7.5M

Runway

18.7 mo

Revenue

$94.0M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2028
Today~21 mo out
Catalyst within runway

Pipeline (4 candidates)

Frequently asked questions

How many drug candidates are in IMMUCOR INC's pipeline?

IMMUCOR INC (BLUD) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is IMMUCOR INC's lead drug candidate?

IMMUCOR INC's most advanced tracked candidate is ksort (Approved) for Predict organ rejection and graft injury in kidney recipients.

What is IMMUCOR INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, IMMUCOR INC has approximately 18.7 months of cash runway.

Get the full picture on IMMUCOR INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.